Clinical trials: Menopausal Vasomotor Symptoms
Hot Flashes
Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
- Trial name
- NCT00314964
- Testing
- PD-0299685
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 527 people
- Sponsor
- Pfizer
Vasomotor Symptoms (VMS)
Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)
The purpose of this study is to determine the effective dose or dose range of AR08 in the treatment of VMS in menopausal females.
- Trial name
- NCT02049164
- Testing
- AR08
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Arbor Pharmaceuticals, Inc.
Menopause
Satavari and Ashoka for Menopause (SAM) Study
This 12-week randomized, placebo-controlled clinical trial will evaluate the efficacy and safety of a daily oral supplement containing Ashoka Bark and Shatavari in women experiencing menopausal symptoms.
- Trial name
- SAM (NCT07861295)
- Testing
- Ashoka Bark and Shatavari
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Vidya USA Corporation
Hot Flashes, Hot Flushes
Stellate Ganglion Blockade in Post-Menopausal Women
Hot flashes and night sweats (vasomotor symptoms, VMS) affect 80% of women during the menopausal transition (MT). VMS are associated with decreased quality of life, increased depressive and anxiety symptoms, memory complaints…
- Conditions
- Hot Flashes, Hot Flushes, Vasomotor Symptoms
- Trial name
- R01 (NCT02907983)
- Testing
- Stellate Ganglion Block Injection with Bupivicaine, Saline injection
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwestern University
Hot Flashes
A Clinical Trial Assessing Safety of MF101 for Hot Flushes
This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks.
- Trial name
- NCT01300078
- Testing
- MF101
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionovo
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Vasomotor Symptoms
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause.
- Trial name
- NCT00401245
- Testing
- desvenlafaxine succinate sustained release
- Where
- 74 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Pfizer
Vasomotor Symptoms
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
The purpose of the study is to evaluate the efficacy and safety of Desvenlafaxine Succinate (DVS) Sustained Release (SR), in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) in menopausal women.
- Trial name
- NCT00683800
- Testing
- desvenlafaxine succinate (DVS) SR
- Where
- 121 sites in United States, Canada
- Volunteers
- 2,186 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vasomotor Symptoms, Menopause
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot…
- Trial name
- NCT05312567
- Testing
- FP-101
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Fervent Pharmaceuticals
Depression, Menopause
Duloxetine for Menopausal Depression
The primary objective of the study is to determine if an eight-week intervention with duloxetine significantly reduces depressive symptoms in symptomatic menopausal women.
- Conditions
- Depression, Menopause, Vasomotor Symptoms
- Trial name
- NCT01117857
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Vasomotor Symptoms
Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause
The purpose of this study is to assess the efficacy and safety of 4 doses of desvenlafaxine-233 sustained release (DVS-233 SR) as compared to placebo for the treatment of moderate to severe vasomotor symptoms associated with…
- Trial name
- NCT00421031
- Testing
- DVS-233 SR
- Where
- 41 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Post Menopausal
Effects of Progressive Resistance Training Vasomotor Symptoms in Post Menopausal Women
The study will be a randomized clinical trial and will be conducted in Civil Hospital and Kalsoom Hospital Samundry. This study will be completed in time duration of 10 months after the approval of synopsis.
- Trial name
- NCT06166264
- Testing
- Progressive resistance training, Control group
- Where
- Pakistan
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Hot Flashes
A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause
Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes.
- Trial name
- Starlight 3 (NCT06206421)
- Testing
- Fezolinetant
- Where
- 24 sites in Japan
- Volunteers
- 277 people
- Sponsor
- Astellas Pharma Inc
Vasomotor Symptoms
Effect of Yoga on Objective and Subjective Menopausal Hot Flashes
The purpose of this research study is to compare yoga and health and wellness classes for helping perimenopausal or newly postmenopausal women who are experiencing hot flashes.
- Trial name
- GLAM (NCT01073397)
- Testing
- Yoga
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Aromatherapy
The Effect of Aromatherapy to Women With Vasomotor Complaints on Menopausal Quality of Life and Vasomotor Symptoms
Evaluation of the effect of aromatherapy applied to women with vasomotor complaints on menopausal quality of life and vasomotor symptoms.
- Trial name
- Aromatherapy (NCT06035380)
- Testing
- mint oil group, rose oil group
- Where
- Cyprus
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Eastern Mediterranean University
Menopause Syndrome
Effects of Connective Tissue Manipulation on Menopausal Symptoms
Menopause is defined as the permanent cessation of menstruation as a result of the loss of ovarian follicular function. This process involves some bothersome physical and psychological climacteric symptoms.
- Trial name
- NCT05293860
- Testing
- Connective tissue manipulation, Superficial massage with the head of the therapeutic ultrasound device
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Hacettepe University
Vasomotor Symptoms Associated With Menopause
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Trial name
- NCT00234819
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 7 sites in United States
- Volunteers
- 325 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Menopause, Menopause Related Conditions
Hot Water Therapy for the Treatment of Menopause-related Hot Flashes
The purpose of this research is to determine whether hot water therapy (i.e. taking prolonged hot baths on multiple consecutive days) decreases hot flash symptoms and improves mood in women who are undergoing or who have…
- Conditions
- Menopause, Menopause Related Conditions, Menopause Syndrome
- Trial name
- NCT06192329
- Testing
- Hot water therapy, Warm water immersion
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Colorado, Colorado Springs